DDInter1429 DDInter1676
Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the gas-filled bubbles and the blood around them creates an increased level of contrast visible in the resulting ultrasound image. During echocardiography, activated Perflutren enhances images of the inner edges or borders of the heart, producing an improved image that may enable physicians to better diagnose patients.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Perflutren {u} (Compound) resembles {v} (Compound) Sevoflurane
Perflutren {u} (Compound) is included by {v} (Pharmacologic Class) Ultrasound Contrast Activity
Perflutren {u} (Compound) causes {v} (Side Effect) Haemoglobin
Perflutren {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Perflutren {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lactulose
Perflutren {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Perflutren {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Perflutren {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Perflutren (Compound) resembles Sevoflurane (Compound)
Perflutren (Compound) is included by Ultrasound Contrast Activity (Pharmacologic Class)
Perflutren (Compound) causes Haemoglobin (Side Effect)
Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Lactulose
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine
Perflutren may lead to a major life threatening interaction when taken with Cabozantinib
Perflutren may lead to a major life threatening interaction when taken with Anagrelide